|
|
|
Agenda
The ADMET Europe sessions will be held in parallel to the two tracks of Screening Europe and MedChem Europe sessions: Sessions Overview
Day 1 – February 19
|
8:30 |
Registration
|
|
9:30 |
Toxicology & Safety Pharmacology
Chaired by Richard Walmsley, Professor of Genetics, University of Manchester
|
|
9:35 |
Improving the Accuracy of Genotoxic Hazard Assessment
Richard Walmsley, Professor of Genetics, University of Manchester
Current in vitro mammalian genotoxicity assays produce positive results for compounds which are negative in vivo (i.e. low specificity). New protocols allowing the assessment of metabolic conversions in GADD45a genotoxic hazard assessment will be described.
|
|
10:05 |
Microelectrode Array-Based Biosensors and Their Applications in Drug Screening and Safety Pharmacology
Elke Guenther, Head, Natural & Medical Sciences Institute, Tübingen University
Three examples of MEA biosensor applications developed for drug screening and safety pharmacology aspects in the field of cardiac and CNS research will be described.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
Quantitative High-Throughput Screening for Cell-Based Toxicity Assays
Menghang Xia, Team Leader of Cellular Toxicity & Signalling, NIH
qHTS resulting large data sets will be presented as providing a rich source of information for the development of in vitro toxicological signatures and leading to the prediction of toxic effects of new chemical entities.
|
|
11:50 |
Automation and Performance Assessment of a Basal Cytotoxicity Assay Intended for Regulatory Safety Assessment
Mounir Bouhifd, Operations Manager of Automated in vitro Testing Facility, EC Joint Research Centre
Assay assessment and validation in the context of regulatory toxicity, and specifically, the automation of a basal cytotoxicity assay (3T3/NRU), subject of an international validation study and successfully implemented at the JRC, will be discussed.
|
|
12:20 |
Lunch & networking in exhibition hall
|
|
12:50 |
 GE Healthcare Workshop: Applications of Microcarrier Cultured Cryopreserved Cells in Screening Assays for GPCRs
|
|
13:20 |
Poster viewing
|
|
14:00
|
Multiplexing ADME-Tox Cell-Based Assays Using Primary Cells
Terry L. Riss, Director of Project Management, Promega Corporation
How related requirements to improve informational content and reduce primary cell and stem cell numbers for ADMET studies will be examplified with CYP450 activity & hepatocyte viability and GSH levels and cytotoxicity.
|
|
14:30 |
The hERG Potassium Channel: Gating to Inactivated Conformation Changes the Potency of a Range of Drugs — Relevance to the Short QT Syndrome
Harry Witchel, Senior Lecturer, Brighton & Sussex Medical School
The inactivation of the hERG potassium channel was titrated using the mutants S631A, N588K and the S631A/N588K double-mutant, demonstrating that mutations at these sites are synergistic in attenuating inactivation and also in reducing drug-induced blockade, particularly by high-specificity blockers.
|
|
15:00 |
Coffee break and networking in exhibition hall
|
|
15:45 |
Transporters in ADME
Chaired by Balazs Sarkadi, Director of Research, National Medical Centre |
|
15:50 |
The Role of ABC Transporters in Drug Absorption, Metabolism, Excretion and Toxicology (ADME-TOX)
Balazs Sarkadi, Director of Research, National Medical Centre
How the human ATP-Binding Cassette (ABC) transporters modulate the pharmacological effects of drugs, and how this predictable ADME-TOX modulation can be used in the process of drug discovery and development will be described.
|
|
16:20 |
A Dominant Role for Transporters in Xenobiotic Uptake?
Paul Dobson, Cheminformatics Research Associate, Manchester Interdisciplinary Biocentre, University of Manchester
Transporter-mediated drug uptake across membranes is usually considered exceptional against the dominant background of diffusion via lipid. Several lines of evidence, including hundreds of examples from the literature, suggest that transporters actually provide the major route of uptake.
|
|
16:50 |
Cinderella’s Shoe for Biological Action Modelling
Vladimir Potemkin, Dean of Chemical Department, Chelyabinsk State University
The new “Cinderella’s Shoe” method creates flexible receptor models and simulates all kinds of molecular movement of drugs. The method allows the bioactive prediction of compounds in dynamic conditions.
|
|
17:20 |
Drinks reception compliments of HTScreening.net |
Day 2 – February 20
|
8:00 |
 TTP Labtech Workshop: Achieving Acurate Nanolitre Pipetting for Miniaturising Serial Dilutions and Assay-Ready Plates
|
| 9:30 |
Optimisation of ADME Properties
Chaired by Holger Fischer, Scientific Specialist, F. Hoffmann-La Roche
|
| 9:35 |
Towards a Multidimensional Optimization in the Field of ADME-Tox: Strategies & Case Studies
Holger Fischer, Scientific Specialist, F. Hoffmann-La Roche
Early phase of drug discovery increasing parameters make the optimization of molecules by discrete structural modifications more and more challenging. Strategies on how this can be handled are discussed on the basis of selected case studies.
|
| 10:05 |
High Throughput Mass Spectrometry: CYP450 Inhibition HTS Assays for Individual (Unpooled) Human Liver Preparations and Label-Free Drug Probes Using RF-MS / 6410 Technology
Can Özbal, Vice President and General Manager, RapidFire Products, BioTrove
Individual (unpooled) human liver preparations were assessed in CYP450 inhibition HTS assays using liver microsomes and unlabelled, native drug probes for FDA-recommended substrates. The high throughput (five seconds per sample) RF-MS /6410 platform afforded comparison of individual tissue samples.
|
|
10:35 |
Coffee break and networking in exhibition hall
|
|
11:20 |
Rescuing ADME Properties - Prodrugs and Other Tricks
Hugo Kubinyi, Retired Professor, University of Heidelberg
Prodrugs, soft drugs and targeted drugs enhance the bioavailability and selectivity of drug candidates. Examples will be presented to illustrate these approaches as well as guidelines for the modification of chemical structures, to modulate ADME properties in the right manner.
|
| 11:50 |
From Drug Discovery to Drug Design: Uncertain Models to Certain Success?
Matthew Segall, Senior Director ADMET, BioFocus DPI
In spite of the inherent uncertainty of current in silico and in vitro models of molecular properties, both may be highly effective if applied appropriately for multi-objective optimisation in drug discovery. A novel paradigm will be illustrated using practical examples.
|
| 12:20 |
Lunch & networking in exhibition hall
|
|
13:00 |
Poster viewing
|
| 13:30 |
ADME Prediction
Chaired by Mario Lobell, Computational Chemist, Bayer HealthCare
|
|
13:35 |
Clinical Pharmacokinetic and Toxic Consequences of the Induction of Transporters and Drug Metabolising Enzymes
Nicola Hewitt, Scientific Consultant, SWS/DMPKORE
An overview of inducers of human hepatic and extra-hepatic metabolising enzymes and transporter proteins, in vitro methodologies; and the clinical pharmacokinetic and toxic consequences of such induction.
|
|
14:05 |
Coffee break and networking
|
| 14:35 |
Applications of an ADME Knowledge Database for Predictive Models and Drug-Drug Interactions Assessment
Ismail Ijjaali, Application Scientist, Aureus Pharma
A knowledge-based scheme for building ADME-Tox predictive models and the assessment of drug-drug interactions will be presented.
|
|
15:05 |
In silico ADMET Traffic Lights and PhysChem Scores and Their Application to Kinase Inhibitors
Mario Lobell, Computational Chemist, Bayer HealthCare
A system for the in silico ADMET characterization of HTS hit structures will be introduced. The generated output is easy to interpret due to the intuitive traffic light colour scheme and a scoring system in the convenient range from 0-10.
|
| 15:35 |
Biological Spectra Analysis: Linking Activity Profiles to Molecular Toxicity
Peter Fedichev, Chief Scientific Officer, Quantum Pharmaceuticals
Toxicity prediction is inherently limited by the limited diversity of toxicity data available. The group reports an entirely new approach for toxicity prediction which is based on different paradigm and thus avoids major difficulties of common approaches.
|
| 16:05 |
Close of conference |
|